SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 16, 2007
CardioVascular BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-51172 | | 33-0795984 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
1635 Village Center Circle, Suite 250 Las Vegas, Nevada | | 89134 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: 702-839-7200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registration under any of the following provisions:
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(k) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | | | |
| Item 8.01 Other Events |
| |
| | CardioVascular BioTherapeutics, Inc. (the “Company”) developed a glossy document titled the 2007 Annual Review to complement the information in the Company’s Annual Report on Form 10-K and its Notice and definitive Proxy Statement for the 2007 Annual Meeting of Stockholders on Schedule 14A, each filed with the Securities and Exchange Commission and each mailed on or about April 16, 2007 to all shareholders of record as of March 30, 2007. As of the date of this filing, the Company is now starting to provide this 2007 Annual Review to shareholders, investors and other parties in addition to or subsequent to the Form 10-K and Schedule 14A. |
| |
| | A copy of this 2007 Annual Review is furnished as Exhibit 99.1 to this report. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date of this report, regardless of any general incorporation language in the filing. |
|
| Item 9.01 Financial Statements and Exhibits |
| |
| (c) | | Exhibits |
| | |
| | 99.1 | | CardioVascular BioTherapeutics, Inc. 2007 Annual Review. |
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | CARDIOVASCULAR BIOTHERAPEUTICS, INC. |
| | |
| Date: May 16, 2007 | | By: | | /s/ Mickael A. Flaa |
| | | | Mickael A. Flaa |
| | | | Chief Financial Officer |
-3-
EXHIBIT INDEX
| 99.1 | CardioVascular BioTherapeutics, Inc. 2007 Annual Review. |
-4-
